Document Detail

Niacin: from mechanisms of action to therapeutic uses.
MedLine Citation:
PMID:  20167004     Owner:  NLM     Status:  MEDLINE    
Niacin has broad spectrum lipid modifying and anti-atherosclerotic properties. It is the most effective medication available for raising raise high density lipoprotein (HDL) levels. Despite statin therapy there remains a considerable residual cardiovascular risk attributed to low HDL levels. Currently, statins decrease cardiovascular events and death by about 25-40%. Trials with surrogate endpoints have shown a decrease in endpoints by 60-90% when a combination of statin and niacin has been used. There is a growing interest in niacin in combination therapy to fill the treatment gap by modifying lipid parameters other than low density lipoprotein cholesterol. This review addresses the role of niacin in comprehensive lipid management with an emphasis on its mechanism of action, formulations, side effects, evidence from clinical trials and also focuses on practical issues related to niacin therapy.
M A Al-Mohaissen; S C Pun; J J Frohlich
Related Documents :
16996864 - Usefulness of follow-up low-density lipoprotein cholesterol level as an independent pre...
19920934 - Pleiotropic vasoprotective effects of statins: the chicken or the egg?
15816994 - Effects of simvastatin on blood lipids, vitamin e, coenzyme q10 levels and left ventric...
217894 - Effects of 3-hydroxy-3-methylglutaric acid on plasma and low-density lipoprotein choles...
11224154 - The effect of d-fenfluramine on intake of carbohydrate supplements is influenced by the...
20412924 - Effect of diet on fecal and urinary estrogenic activity.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Mini reviews in medicinal chemistry     Volume:  10     ISSN:  1875-5607     ISO Abbreviation:  Mini Rev Med Chem     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-04-23     Completed Date:  2010-07-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101094212     Medline TA:  Mini Rev Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  204-17     Citation Subset:  IM    
Healthy Heart Program, St. Paul's Hospital, Department of Pathology and Laboratory Medicine and the University of British Columbia, Vancouver BC, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Drug Compounding
Lipoproteins, HDL / metabolism
Niacin / adverse effects,  metabolism*,  therapeutic use
Receptors, Nicotinic / metabolism
Reg. No./Substance:
0/Lipoproteins, HDL; 0/Receptors, Nicotinic; 59-67-6/Niacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimer's Disease?
Next Document:  The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and ap...